[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Shaikh Zayed Hospital, Lahore\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":128},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,44,71,105],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100638905","effectiveness-of-oral-magnesium-supplementation-in-fibromyalgia-patients-not-responding-to-standard-treatment-100638905",false,"NCT07585045","Effectiveness of Oral Magnesium Supplementation in Fibromyalgia Patients Not Responding to Standard Treatment","Effectiveness of Oral Magnesium Supplementation in Fibromyalgia Patients Not Responding to Standard Treatment: A Randomized Clinical Trial Using Revised Fibromyalgia Impact Questionnaire","Inclusion Criteria:\n\n1. Patients diagnosed with FM according to the American College of Rheumatology (ACR) 2016 criteria\n2. Age: 18-65 years.\n3. Not responding to conventional treatment (e.g., amitriptyline, duloxetine, pregabalin) for at least 8 weeks\n4. Patients giving informed consent for enrollment in the study.\n\nExclusion Criteria:\n\n* 1- Patients with renal impairment 2- Pregnant or lactating women 3- Already on magnesium or other mineral supplements 4- Known cases of inflammatory arthritis or other chronic pain syndromes","ALL","18 Years","65 Years",{"count":20,"type":21},86,"ESTIMATED","INTERVENTIONAL",[24],"NA","Fibromyalgia is a complex widespread pain disorder. OBJECTIVES To evaluate the effectiveness of oral magnesium supplementation in reducing symptom severity among fibromyalgia patients who have not responded to standard treatment, using validated scoring systems such as the Fibromyalgia Impact Questionnaire Revised (FIQR).",[27],"Fibromyalgia",[27,29,30],"Magnesium supplement","Revised Fibromyalgia Impact Questionnaire","RECRUITING","2026-05-08",{"date":34,"type":35},"2026-05-13","ACTUAL",{"date":37,"type":35},"2026-04-16",{"date":39,"type":21},"2027-02-26",{"name":41,"class":42},"Shaikh Zayed Hospital, Lahore","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":43},"100635602","phase-4-major-adverse-cardiovascular-events-mace-in-rheumatoid-arthritis-patient-with-moderate-to-severe-disease-activity-treated-with-tofacitinib-and-statins-vs-tnf-inhibitors-tofstat-clinical-trial-100635602","NCT07554820","Major Adverse Cardiovascular Events (MACE) in Rheumatoid Arthritis Patient With Moderate to Severe Disease Activity Treated With Tofacitinib and Statins vs TNF Inhibitors: TOFSTAT CLINICAL TRIAL","TOFSTAT","Inclusion Criteria:\n\n* • RA diagnosis with moderate to severe disease activity, based on DAS-28 despite on \\> 2 conventional DMARDs.\n\n  * One or more CVD risk factors, such as hypertension, diabetes, smoking, high cholesterol, etc.\n  * Age 50 or older.\n\nExclusion Criteria:\n\n* Known contraindications to statins.\n\n  * History of major adverse CV events (e.g., recent myocardial infarction or stroke).\n  * Pregnancy or breastfeeding.","50 Years","85 Years",{"count":54,"type":21},120,[56],"PHASE4","The rationale of our study is to observe the incidence of MACE in RA patients treated with tofacitinib along with statins with one or more cardiovascular disease risks.\n\nPRIMARY OBJECTIVE\n\n* To determine the incidence of MACE in Rheumatoid Arthritis patients with moderate to high disease activity and with one or more cardiovascular disease risks, which are non-responsive to standard conventional DMARDs (cDMARDs) treatment and are prescribed Tofacitinib 5 mg twice daily along with statin 20 mg daily versus TNF Inhibitors.\n* The study aim to compare MACE in RA patients treated with tofacitinib and statin versus TNF inhibitors.",[59,60],"Rheumatoid Arthritis","Major Adverse Cardiac Events",[62],"rheumatoid arthritis, Major adverse cardiac event, tofacitinib","2026-04-21",{"date":65,"type":35},"2026-04-28",{"date":67,"type":35},"2025-12-06",{"date":69,"type":21},"2026-09-30",{"name":41,"class":42},{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":83,"briefSummary":84,"conditions":85,"keywords":90,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":4},"100605279","phase-4-levocarnitine-for-reducing-esa-requirements-in-hemodialysis-patients-with-renal-anemia-100605279","NCT07160452","Levocarnitine for Reducing ESA Requirements in Hemodialysis Patients With Renal Anemia","Effect of Levocarnitine Injections on Reducing Erythropoietin-Stimulating Agent Requirements in Hemodialysis Patients With Renal Anemia","L-CAR-ESA","Inclusion Criteria:\n\n1. Both male and female patients\n2. Patients aged 20-60 years.\n3. Patients undergoing maintenance hemodialysis three times a week for at least six months\n4. Patients having renal anemia\n\nExclusion Criteria:\n\n1. Patients currently using any carnitine preparation as a supplement (to avoid confounding effects from additional carnitine intake).\n2. Patients on immunosuppressive drugs, steroids, or antibiotics (to avoid the influence of these medications on anemia and carnitine metabolism).\n3. Patients who have previously received levocarnitine in either oral or injected form (to eliminate any prior influence of levocarnitine on study outcomes).\n4. Patients with a history of blood transfusion within the past 6 months (to exclude the immediate impact of transfusions on hemoglobin levels and anemia management).\n5. Patients with acute inflammation (to prevent interference with study parameters as inflammation can affect anemia status).\n6. Patients with communication difficulties due to dementia or other factors (to ensure accurate symptom reporting and study adherence).","20 Years","60 Years",{"count":82,"type":21},94,[56],"Renal anemia is common in people receiving long-term hemodialysis and is usually treated with erythropoiesis-stimulating agents (ESAs). Some patients respond poorly and require high ESA doses, which increases treatment burden, cost, and potential side effects. Carnitine deficiency is frequent in hemodialysis because carnitine is lost during dialysis and its synthesis is reduced. Levocarnitine may improve red blood cell function and reduce the dose of ESA needed to maintain hemoglobin.\n\nThis single-center, randomized controlled trial will test whether adding intravenous levocarnitine to standard care reduces ESA requirements in adults on maintenance hemodialysis who have renal anemia. Ninety-four participants (age 20-60 years) on thrice-weekly hemodialysis for ≥6 months and with hemoglobin \\\u003C10 g\u002FdL will be randomly assigned (1:1) to:\n\nIntervention: Levocarnitine 1,000 mg IV three times per week, administered after each dialysis session, plus usual anemia care including ESA per unit protocol.\n\nControl: Usual anemia care including ESA per unit protocol without levocarnitine.\n\nParticipants will be followed for 6 months. Hemoglobin, hematocrit, ESA dose, and the erythropoietin responsiveness index (ERI = monthly ESA dose ÷ \\[dry weight × average hemoglobin\\]) will be recorded monthly.\n\nThe primary outcome is the ESA dose (units\u002Fweek) at month 6. Secondary outcomes include ERI and monthly changes in hemoglobin and hematocrit, along with routine safety monitoring. If levocarnitine lowers ESA needs, the findings may offer a cost-effective strategy to optimize anemia management in hemodialysis patients.",[86,87,88,89],"Anemia","Kidney Failure","End-Stage Renal Disease","Renal Dialysis",[91,92,93,94,95],"Levocarnitine","L-carnitine","Erythropoiesis-Stimulating Agents","Erythropoietin Responsiveness Index","Hematocrit","NOT_YET_RECRUITING","2025-09-06",{"date":99,"type":35},"2025-09-12",{"date":101,"type":21},"2025-09-15",{"date":103,"type":21},"2026-03-15",{"name":41,"class":42},{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":16,"minAge":112,"maxAge":113,"enrollmentInfo":114,"targetDuration":4,"studyType":22,"phases":116,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":43},"100594244","early-vs-conventional-enteral-nutrition-after-uncomplicated-paediatric-open-appendectomy-100594244","NCT07016919","Early vs Conventional Enteral Nutrition After Uncomplicated Paediatric Open Appendectomy","Early vs Conventional Enteral Nutrition After Uncomplicated Paediatric Open appendectomy-a Randomised Control Trial","Inclusion Criteria:\n\n* Age 6-14years\n* Both male\\& female\n* Uncomplicated appendicitis(no perforation\u002Fgangrene)\n* patients who underwent open appendectomy\n* ASA grade 1 only\n* willing to participate and follow up\n\nExclusion Criteria:\n\n* Any underlying comorbidities or organ dysfunction for example renal,GI, respiratory, congenital heart disease\n* severe protein caloric malnourishment or obesity BMI\\>25\n* any past surgical history related to gut\n* any associated malignancy\n* prolonged surgery(anesthesia time\\>3hours)\n* complicated appendicitis (gangrene, perforation,intra-abdominal abscess)\n* post-op shock\n* ongoing infection\n* GI dysfunction such as gastroesophageal reflux disease\u002Fobstruction.","6 Years","14 Years",{"count":115,"type":21},88,[24],"This clinical trial is conducted to see if after surgery of appendix(open appendectomy) in children giving oral nutrition within 6hours of surgery instead of older method of starting oral nutrition after 24hours of surgery improves the outcome or not which is the length of hospital stay(from the day of surgery until discharge) and to look for complications associated with oral nutrition (nausea, vomiting, abdominal distension, diarrhea) as well as return of bowel activity after surgery that is passage of flatus(gas) and stool.Participants after taking informed consent are enrolled in two groups,group A in which oral nutrition is started in 6hours and group B in which oral nutrition is started after 24hours of surgery and then see for the outcome during hospital stay until 1week after discharge on follow up.",[119],"Uncomplicated Acute Appendicitis in Children","2025-06-11",{"date":122,"type":35},"2025-06-15",{"date":124,"type":35},"2025-03-20",{"date":126,"type":21},"2025-10",{"name":41,"class":42},""]